Lymphoproliferative Diseases in Renal Allograft Recipients

  • Douglas W. Hanto
  • Glauco Frizzera
  • Kazimiera J. Gajl-Peczalska
  • David T. Purtilo
  • Richard L. Simmons


The incidence of lymphoproliferative disorders (LPD) is increased in many groups of immune deficient patients — recipients of organ transplants, individuals with genetically determined immunodeficiency or autoimmune diseases, and patients following chemotherapy or radiation therapy (20, 35, 36, 46). Because of their histological features and clinical aggressiveness, these lymphoproliferations have been labelled malignant lymphomas in renal allograft recipients.


Renal Transplant Recipient Lymphoproliferative Disorder Infectious Mononucleosis Renal Allograft Recipient Heterophil Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson, J.L., Bieber, C.P., Fowles, R.E., and Stinson, E. Idiopathic cardiomyopathy, age, and suppressor-cell dysfunction as a risk determinants of lymphoma after cardiac transplantation. Lancet, ii:1174, 1978.CrossRefGoogle Scholar
  2. 2.
    Britton, S., Anderson-Anvret, M., Gergely, P., Henle, W., Jondal, M., Klein, G., Sandstedt, B., and Svedmyr, E. Epstein-Barr-virus immunity and tissue distribution in a fatal case of infectious mononucleosis. N. Engl. J. Med., 298:89, 1978.PubMedCrossRefGoogle Scholar
  3. 2a.
    Calne, R.Y., Roller, K., Thiru, S., McMaster, P., Craddock, G.N., Aziz, S., White, D.J.G., Evans, D.B., Dunn, D.C., Henderson, R.G., and Lewis, P. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreas, and 2 livers. Lancet, ii:1033, 1979.CrossRefGoogle Scholar
  4. 3.
    Chang, R.S., Lewis, J.P., and Abildgaard, C.F. Prevalence of oropharyngeal excreters of leukocyte-transforming agents among a human population. N. Engl. J. Med., 289:1325, 1973.PubMedCrossRefGoogle Scholar
  5. 4.
    Chang, R.S., Lewis, J.P., Reynolds, R.D., Sullivan, M.J., and Neuman, J. Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. Ann. Intern. Med., 88:34, 1978.PubMedGoogle Scholar
  6. 5.
    Cheeseman, S.H., Henle, W., Rubin, R.H., Tolkoff-Rubin, N.E., Cosimi, B., Cantell, K., Winkle, S., Herrin, J.T., Black, P.H., Russell, P.S., and Hirsch, M.S. Epstein-Barr virus infections in renal transplant recipients. Effects of antithymocyte globulin and interferon. Ann. Intern. Med., 93:39, 1980.PubMedGoogle Scholar
  7. 6.
    Colby, B.M., Shaw, J.E., Elion, G.B., and Pagano, J.S. Effect of Acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J. Virol., 34:560, 1980.PubMedGoogle Scholar
  8. 7.
    Datta, A.K., Colby, B.M., Shaw, J.E., and Pagano, J.S. Acyclovir inhibition of Epstein-Barr virus replication. Proc. Natl. Acad. Sci., USA, 77:5163, 1980.PubMedCrossRefGoogle Scholar
  9. 8.
    Elion, G.B., Furman, P.A., Fyfe, J.A., de Miranda, P., Beauchamp, L., and Schaeffer, H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxy-ethoxymethyl) guanine. Proc. Natl. Acad. Sci., USA, 74:5716, 1977.PubMedCrossRefGoogle Scholar
  10. 9.
    Frank, A., Andiman, W., and Miller, G. Epstein-Barr virus and nonhuman primates: natural and experimental infection. Adv. Cancer Res., 23:171, 1976.PubMedCrossRefGoogle Scholar
  11. 10.
    Frizzera, G., Hanto, D.W., Gajl-Peczalska, K.J., Rosai, J., McKenna, R.W., Sibley, R.K., Holahan, K.P., and Lindquist, L.L. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res., 4l:4253, 1981.Google Scholar
  12. 11.
    Gleichmann, E., Gleichmann, H., Schwartz, R.W., Weinblatt, Al, and Armstrong, M.Y.K. Immunologic induction of malignant lymphoma: identification of donor and host tumors in the graft-versus-host model. J. Natl. Cancer Inst., 54:107, 1975.PubMedGoogle Scholar
  13. 12.
    Hanto, D.W., Frizzera, G., Gajl-Peczalska, K., Purtilo, D.T., Klein, G., Simmons, R.L., and Najarian, J.S. The Epstein-Barr virus (EBV) in the pathogenesis of posttransplant lymphoma. Transplant. Proc., 13:756, 1981.PubMedGoogle Scholar
  14. 13.
    Hanto, D.W., Sakamoto, K., Purtilo, D.T., Simmons, R.L., and Najarian, J.S. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Surgery, 90:204, 1981.PubMedGoogle Scholar
  15. 14.
    Hanto, D., Frizzera, G., Purtilo, D.T., Sakamoto, K., Sullivan, J., Saemundsen, A.K., Klein, G., Simmons, R.L., and Najarian, J.S. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res., 41:4253, 1981.PubMedGoogle Scholar
  16. 15.
    Hanto, D., Frizzera, G., Gajl-Peczalska, K., Sakamoto, K., Purtilo, D.T., Balfour, H., Simmons, R.L., and Najarian, J.S. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. N. Engl. J. Med., 306:913, 1982.PubMedCrossRefGoogle Scholar
  17. 16.
    Hanto, D., Frizzera, G., Gajl-Peczalska, K.J., Simmons, R.L., Najarian, J.S., and Balfour, H.H., Jr. N. Engl. J. Med., 307:896, 1982.CrossRefGoogle Scholar
  18. 17.
    Henle, G. and Henle, W. The virus as the etiologic agent of infectious mononucleosis. In: M.S. Epstein and B.G. Achong (eds.), The Epstein-Barr Virus, pp. 297–320. New York: Springer-Verlag, 1979.CrossRefGoogle Scholar
  19. 18.
    Henle, W. and Henle, G. Epstein-Barr virus (EBV) in related serology in Hodgkin’s disease. Natl. Cancer Inst. Monogr., 36:79, 1973.PubMedGoogle Scholar
  20. 19.
    Hertel, B.F., Rosai, J., Dehner, P., and Simmons, R.L. Lymphoproliferative disorders in organ transplant recipients. Lab. Invest., 36:340, 1977Google Scholar
  21. 20.
    Hoover, R. and Farumeni, J.F., Jr. Risk of cancer in renal-transplant recipients. Lancet, ii:55, 1973.CrossRefGoogle Scholar
  22. 21.
    Howard, R.J., Miller, J., and Najarian, J.S. Cytomegalo-virus-induced immune suppression. II. Cell mediated immunity. Clin. Exp. Immunol., 18:119, 1974.PubMedGoogle Scholar
  23. 22.
    Howard, R.J. and Najarian, J.S. Cytomegalovirus-induced immune suppression. I. Humoral immunity. Clin. Exp. Immunol., 18:109, 1974.PubMedGoogle Scholar
  24. 23.
    Johansson, B., Klein, E., and Haglund, S. Correlation between the presence of surface localized immunoglobulin (Ig) and the histological type of human malignant lymphomas. Clin. Immunol. Immunopathol., 5:119, 1976.PubMedCrossRefGoogle Scholar
  25. 24.
    Jondal, M. and Klein, G. Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. J. Exp. Med., 138:1365, 1973.PubMedCrossRefGoogle Scholar
  26. 25.
    Klein, G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc. Natl. Acad. Sci., USA, 76:2442, 1979.PubMedCrossRefGoogle Scholar
  27. 26.
    Klein, G. The relationship of the virus to nasopharyngeal carcinoma. In: M.A. Epstein and B.G. Achong (eds.), The Epstein-Barr Virus. pp. 339–350. New York: Springer-Verlag, 1979.CrossRefGoogle Scholar
  28. 27.
    Klein, G. and Klein, E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc. Natl. Acad. Sci., USA, 74:2121, 1977.PubMedCrossRefGoogle Scholar
  29. 28.
    Lipinski, M., Tursz, T., Kreis, H., Finale, Y., and Amiel, J.L. Dissociation of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity in kidney allograft recipients receiving high-dose immunosuppressive therapy. Transplantation (Baltimore), 29:214, 1980.Google Scholar
  30. 29.
    Marker, S.C., Ascher, N.L., Kalis, J.M., Simmons, R.L., Najarian, J.S., and Balfour, H.H., Jr. Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients. Surgery (St. Louis), 85:433, 1979.Google Scholar
  31. 30.
    Matas, A.J., Simmons, R.L., and Najarian, J.S. Chronic antigenic stimulation, herpesvirus infection, and cancer in transplant recipients. Lancet, i:1277, 1975.CrossRefGoogle Scholar
  32. 31.
    Miller, G. Experimental carcinogenicity by the virus in vivo. In: M.A. Epstein and B.G. Achong (eds.), The Epstein-Barr Virus, pp. 352–372. New York: Springer-Verlag, 1979.Google Scholar
  33. 32.
    Nilsson, K., Giovanella, B.C., Stehlin, J.S., and Klein, G. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int. J. Cancer, 19:337, 1977.PubMedCrossRefGoogle Scholar
  34. 33.
    Pagano, J.S. and Shaw, J.E. Molecular probes and genome homology. In: M.A. Epstein and B.G. Achong (eds.), The Epstein-Barr Virus, pp. 109–146. New York: Springer-Verlag, 1979.CrossRefGoogle Scholar
  35. 34.
    Penman, H.G. Fatal infectious mononucleosis: a critical review. J. Clin. Pathol., 23:765, 1971.CrossRefGoogle Scholar
  36. 35.
    Penn, I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery (St. Louis), 83:492, 1978.Google Scholar
  37. 36.
    Penn, I. The price of immunotherapy. Curr. Probl. Surg., 18:681, 1981.PubMedCrossRefGoogle Scholar
  38. 37.
    Purtilo, D.T. Epstein-Barr-virus-induced oncogenesis in immune deficient individuals. Lancet, i:300, 1980.CrossRefGoogle Scholar
  39. 38.
    Purtilo, D.T., Paquin, L., DeFlorio, D., Virzi, F., and Sakhuja, R. Immunodiagnosis and immunopathogenesis of the X-linked recessive lymphoproliferative syndrome. Semin. Hematol., 16:309, 1979.PubMedGoogle Scholar
  40. 39.
    Robinson, J.E., Brown, N., Andiman, W., Halliday, K., Francke, U., Robert, M.F., Andersson-Anvret, M., Horstmann, D., and Miller, G. Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus. N. Engl. J. Med., 302:1293, 1980.PubMedCrossRefGoogle Scholar
  41. 40.
    Rosen, A., Gergely, P., Jondal, M., Klein, G., and Britton, S. Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature (London), 267:52, 1977.CrossRefGoogle Scholar
  42. 41.
    Saemundsen, A.K., Purtilo, D.T., Sakamoto, K., Sullivan, J.L., Synnerholm, A-C., Hanto, D.W., Simmons, R., Anvret, M.A., Collins, R., and Klein, G. Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res., 41:4237, 1981.PubMedGoogle Scholar
  43. 42.
    Sakamoto, K., Freed, H.J., and Purtilo, D.T. Antibody Responses to Epstein-Barr virus in families with the X-linked lymphoproliferative syndrome. J. Immunol., 125:921, 1980.PubMedGoogle Scholar
  44. 43.
    Schneck, S.A. and Penn, I. De novo brain tumours in renaltransplant recipients. Lancet, i:983, 1971.CrossRefGoogle Scholar
  45. 44.
    Schooley, R.T., Hirsch, M.S., Calvin, R.B., Cosimi, A.B., Tolkoff-Rubin, N., McCluskey, R.T., Burton, R.C., Russell, P.S., Herrin, J.T., Delmonico, F.L., Giorgi, J.V., Henle, W., and Rubin, R.H. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N. Engl. J. Med., 308:307, 1983.PubMedCrossRefGoogle Scholar
  46. 45.
    Simmons, R.L., Matas, A.J., Rattazzi, L.C., Balfour, H.H., Howard, R.J., and Najarian, J.S. Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation. Surgery (St. Louis), 8:537, 1977.Google Scholar
  47. 46.
    Spector, B.D., Perry, G.S., III, and Kersey, J.H. Genetically determined immunodeficiency diseases (GDID) and malignancy: report from the Immunodeficiency-Cancer Registry. Clin. Immunol. Immunopathol., 11:12, 1978.PubMedCrossRefGoogle Scholar
  48. 47.
    Strauch, B., Andrews, L., Siegel, N., and Miller, G. Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet, i:234, 1974.CrossRefGoogle Scholar
  49. 48.
    Sullivan, J.L., Byron, K.S., Brewster, F.E., and Purtilo, D.T. Deficient natural killer cell activity in the X-linked lymphoproliferative syndrome. Science, 210:543, 1980.PubMedCrossRefGoogle Scholar
  50. 49.
    Svedmyr, E. and Jondal, M. Cytotoxic effector cells specific for B cell lines mononucleosis. Proc. Natl. Acad. Sci., USA, 72:1622, 1975.PubMedCrossRefGoogle Scholar
  51. 50.
    Zulman, J., Jaffe, R., and Talai, N. Evidence that the malignant lymphoma of Sjogrens syndrome is a monoclonal B-cell neoplasm. N. Engl. J. Med., 299:1215, 1978.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1984

Authors and Affiliations

  • Douglas W. Hanto
    • 1
  • Glauco Frizzera
  • Kazimiera J. Gajl-Peczalska
  • David T. Purtilo
    • 2
  • Richard L. Simmons
  1. 1.Departments of Surgery and Laboratory Medicine PathologyUniversity of Minnesota Health Sciences CenterMinneapolisUSA
  2. 2.Departments of Pathology and Laboratory Medicine Pediatrics and the Eppley Institute for Research in Cancer and Allied DiseasesUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations